食卫局:复星供港疫苗将於欧洲生产 科兴北京制疫苗首批明年1月到港
食卫局发言人指,政府与复星医药(02196.HK)达成协议,将会取得最多750万剂由复星与德国药厂BioNTech(BNTX.US)合作研发的mRNA疫苗(即BNT162b2),供港的疫苗将於欧洲生产。第一批100万剂量预计最快可於明年第一季交付。
发言人指,就有关采购协议合约安排复星医药为德国BioNTech在中国的战略合作夥伴,双方将共同在中国大陆及港澳台地区开发、商业化基於BioNTech专有的mRNA技术研发、针对新冠病毒的mRNA疫苗产品。根据协议约定,为本次合作之开发、商业化目的,复星医药产业将负责推进该产品於中国的临床试验、上市申请、市场销售;BioNTech将负责提供区域内临床试验申请所需的技术材料和临床前研究资料、配合区域内临床试验,并供应该等临床试验及市场销售所需的产品。
截至目前,BioNTech研发的mRNA核酸疫苗BNT162b2已获英国批核紧急使用及加拿大卫生部门批核使用,而辉瑞(PFE.US)为德国BioNTech mRNA核酸疫苗中国以外区域的合作夥伴。
至於由科兴向香港提供的疫苗,根据科兴提供的资料,有关疫苗在北京大兴区生产,第一批100万剂量最快可望於明年一月到港。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.